Ligand id: 7581

Name: (S)-crizotinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 77.99
Molecular weight 449.12
XLogP 2.83
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species

Bioactivity Comments
(S)-crizotinib has been reported to inhibit the activity of MTH1 (aka NUDT1) with a Kd of 48nM [1]. (R)-crizotinib is an approved anti-cancer drug, targeting ALK, RON and c-Met protein kinases. However, at NUDT1 (R)-crizotinib is less potent (Kd 781nM) than its (S) counterpart [1]. This highlights the necessity that drug compounds be steroespecifically pure when there is a pharmacological difference in activity between stereoisomers (ie they exhibit distinct molecular mechanisms of action), as enantiomerically impure mixtures may result in off-target effects.
A number of chemical suppliers and other submitters to online chemistry databases specify the non-stereoisomeric molecule depicted in PubChem CID 11597571.